Athena Athena

X

Find Radio Compass News for Minocycline Hydrochloride

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

JDMFs Filed

JDMFs Filed

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

JP

0

Other Listed Suppliers

SERVICES
left grey arrow
right gray arrow
  • INJECTABLE;INJECTION - EQ 100MG BASE/VIAL
  • CAPSULE;ORAL - EQ 100MG BASE
  • CAPSULE;ORAL - EQ 50MG BASE
  • CAPSULE;ORAL - EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • TABLET, EXTENDED RELEASE;ORAL - EQ 105MG BASE
  • TABLET, EXTENDED RELEASE;ORAL - EQ 115MG BASE
  • TABLET, EXTENDED RELEASE;ORAL - EQ 135MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • TABLET, EXTENDED RELEASE;ORAL - EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • TABLET, EXTENDED RELEASE;ORAL - EQ 55MG BASE
  • TABLET, EXTENDED RELEASE;ORAL - EQ 65MG BASE
  • TABLET, EXTENDED RELEASE;ORAL - EQ 80MG BASE
  • TABLET, EXTENDED RELEASE;ORAL - EQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

https://www.globenewswire.com//news-release/2023/10/20/2764004/0/en/Journey-Medical-Corporation-Announces-Data-from-Bioavailability-Study-of-DFD-29-Minocycline-Hydrochloride-Modified-Release-Capsules-40-mg-vs-Solodyn-Minocycline-Hydrochloride-Exten.html

GLOBENEWSWIRE
20 Oct 2023

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-lifesciences-gets-usfda-nod-for-generic-acne-treating-drug/articleshow/101107316.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

ECONOMIC TIMES
20 Jun 2023

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203553

FDA
16 Jun 2023

https://www.globenewswire.com/news-release/2023/06/13/2687130/0/en/Journey-Medical-Corporation-Announces-Positive-Topline-Data-from-Phase-1-Clinical-Trial-Assessing-the-Impact-of-DFD-29-Minocycline-Hydrochloride-Modified-Release-Capsules-40-mg-on-.html

GLOBENEWSWIRE
13 Jun 2023

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214934

FDA
02 Jun 2023

https://ir.bauschhealth.com/news-releases/2023/05-18-2023

PRESS RELEASE
18 May 2023

https://www.clinicaltrialsarena.com/news/journey-medical-ppr-therapy-trial/

CLINICALTRIALSARENA
11 Jan 2023

https://www.globenewswire.com/news-release/2023/01/10/2586177/0/en/Journey-Medical-Corporation-Completes-Enrollment-in-Phase-3-Clinical-Trials-Evaluating-DFD-29-Minocycline-Modified-Release-Capsules-40-mg-for-the-Treatment-of-Papulopustular-Rosace.html

GLOBENEWSWIRE
10 Jan 2023

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204394

FDA
07 Oct 2022

https://www.globenewswire.com/news-release/2022/08/30/2506755/0/en/Journey-Medical-Corporation-Announces-50-Enrollment-Milestone-Achieved-in-Phase-3-Clinical-Trials-Evaluating-DFD-29-Minocycline-Modified-Release-Capsules-40-mg-for-the-Treatment-of.html

GLOBENEWSWIRE
30 Aug 2022

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214934

FDA
22 Jul 2022

https://health.economictimes.indiatimes.com/news/pharma/glenmark-launches-topical-gel-for-treatment-of-moderate-severe-acne/92801284

ET HEALTH
11 Jul 2022

https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-litigation-for-minocycline-hydrochloride-aerosol-foam-1649312464.pdf

FDA
06 Apr 2022

https://www.globenewswire.com/news-release/2021/10/05/2308650/0/en/VYNE-Therapeutics-Announces-its-China-Partner-s-Enrollment-of-First-Patient-in-Phase-3-Study-of-AMZEEQ-in-Patients-with-Moderate-to-Severe-Acne.html

GLOBENEWSWIRE
05 Oct 2021

https://www.globenewswire.com/news-release/2021/01/21/2162077/0/en/VYNE-Therapeutics-Announces-Contract-Execution-for-AMZEEQ-minocycline-and-ZILXI-minocycline-with-Major-Pharmacy-Benefit-Management-PBM-Company.html#:~:text=January%2021%2C%202021%2008%3A00,%7C%20Source%3A%20VYNE%20Therapeutics%20Inc.&text=(Nasdaq%3A%20VYNE)%20(%E2%80%9C,)%20topical%20foam%2C%201.5%25.

GLOBENEWSWIRE
21 Jan 2021

https://www.globenewswire.com/news-release/2020/12/15/2145298/0/en/VYNE-Therapeutics-Announces-New-U-S-Patent-Expiring-in-2037-for-AMZEEQ-minocycline-topical-foam-4.html

GLOBENEWSWIRE
15 Dec 2020

https://www.pharmacompass.com/pdf/news/fda-confirm-paragraph-iv-patent-certifications-minocin-minocycline-hydrochloride-1609403837.pdf

FDA
01 Dec 2020

https://www.globenewswire.com/fr/news-release/2020/12/01/2137415/0/en/VYNE-Therapeutics-Announces-Publication-of-Long-term-Safety-Efficacy-Data-for-ZILXI-minocycline-topical-foam-1-5-in-the-Journal-of-Clinical-and-Aesthetic-Dermatology.html

GLOBENEWSWIRE
01 Dec 2020

https://www.prnewswire.com/news-releases/citius-pharmaceuticals-achieves-chemical-manufacturing-and-control-milestones-for-mino-lok-301135361.html

PRNEWSWIRE
22 Sep 2020

https://www.prnewswire.com/news-releases/therapeutic-solutions-international-reports-synergistic-suppression-of-suicide-associated-neuroinflammatory-pathway-by-quadramune-and-minocycline-301120336.html

PRNEWSWIRE
28 Aug 2020

https://www.prnewswire.com/news-releases/menlo-therapeutics-receives-fda-approval-of-zilxi-minocycline-topical-foam-1-5-the-first-topical-minocycline-treatment-for-rosacea-301067795.html

PRNEWSWIRE
29 May 2020

https://www.globenewswire.com/news-release/2020/05/27/2039354/0/en/Menlo-Therapeutics-Announces-Covered-Status-for-AMZEEQ-minocycline-topical-foam-4-on-Additional-Commercial-Formulary.html

GLOBENEWSWIRE
27 May 2020

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213662

FDA
06 May 2020

https://www.globenewswire.com/news-release/2020/04/23/2020865/0/en/Menlo-Therapeutics-and-Cutia-Therapeutics-Enter-into-Exclusive-License-Agreement-for-AMZEEQ-and-Approved-Topical-Minocycline-Products-in-Greater-China.html

GLOBENEWSWIRE
23 Apr 2020

https://www.globenewswire.com/news-release/2020/04/23/2020976/0/en/Adamis-Pharmaceuticals-Announces-Publication-Demonstrating-PET-Scan-Results-of-Higher-Dose-Naloxone-in-Monkeys.html

GLOBENEWSWIRE
23 Apr 2020

https://www.prnewswire.com/news-releases/foamix-announces-amzeeq-minocycline-achievement-of-preferred-status-on-express-scripts-national-preferred-formulary-one-of-the-largest-commercial-formularies-in-the-us-300986316.html

PR NEWSWIRE
14 Jan 2020

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204453

FDA
20 Dec 2019

https://www.contractpharma.com/contents/view_breaking-news/2019-10-23/foamix-enters-contract-manufacturing-agreement/

CONTRACT PHARMA
23 Oct 2019

https://www.prnewswire.com/news-releases/foamix-receives-fda-approval-of-amzeeq-topical-minocycline-treatment-for-millions-of-moderate-to-severe-acne-sufferers-300941412.html

PR NEWSWIRE
18 Oct 2019

https://www.prnewswire.com/news-releases/foamix-announces-fda-acceptance-of-its-new-drug-application-for-fmx103-minocycline-foam-for-the-treatment-of-moderate-to-severe-papulopustular-rosacea-300940656.html

PR NEWSWIRE
17 Oct 2019

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-2-2019-1570003052.pdf

FDA
02 Oct 2019

https://www.prnewswire.com/news-releases/hovione-announces-successful-end-of-phase-2-meeting-with-the-fda-and-outlines-phase-3-program-for-minocycline-topical-gel-300922397.html

PR NEWSWIRE
23 Sep 2019

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203443

FDA
22 Aug 2019

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202261

FDA
22 Aug 2019

https://health.economictimes.indiatimes.com/news/pharma/zydus-cadilas-acne-drug-receives-usfda-go-ahead/70495524

ECONOMICTIMES
02 Aug 2019

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201467

FDA
02 Aug 2019

http://www.pharmatimes.com/news/nhs_england_scraps_7_more_drugs_on_prescription_1293506

Anna Smith PHARMATIMES
09 Jul 2019

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203443

FDA
23 Apr 2019

https://www.reuters.com/article/us-foamix-fda/foamixs-treatment-for-common-skin-condition-meets-late-stage-trial-goals-idUSKCN1NC1ES

Manas Mishra REUTERS
08 Nov 2018

https://www.prnewswire.com/news-releases/biopharmx-initiates-phase-2b-trial-of-bpx-04-for-rosacea-300729730.html

PR NEWSWIRE
11 Oct 2018

https://www.prnewswire.com/news-releases/biopharmx-initiates-phase-2b-trial-of-bpx-04-for-rosacea-300729730.html

PR NEWSWIRE
11 Oct 2018

https://www.prnewswire.com/news-releases/menarini-group-anuncia-un-acuerdo-comercial-para-vabomere-orbactiv-y-minocin-en-68-pa%C3%ADses-861609999.html

PR NEWSWIRE
11 Oct 2018

https://www.prnewswire.com/news-releases/biopharmx-initiates-phase-2b-trial-of-bpx-04-for-rosacea-300729730.html

PR NEWSWIRE
11 Oct 2018

https://www.prnewswire.com/news-releases/menarini-group-anuncia-un-acuerdo-comercial-para-vabomere-orbactiv-y-minocin-en-68-pa%C3%ADses-861609999.html

PR NEWSWIRE
11 Oct 2018

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202261

FDA
02 Oct 2018

http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-announces-closing-underwritten-public

PRESS RELEASE
29 May 2018

https://www.prnewswire.com/news-releases/us-patent-and-trademark-office-awards-biopharmx-patent-protection-for-novel-tetracycline-class-topical-drug-compositions-300615514.html

PRNEWSWIRE
20 Mar 2018

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204453

FDA
19 Mar 2018

https://www.reuters.com/article/us-impax-labs-lawsuit/impax-broke-u-s-antitrust-law-by-delaying-generic-drug-jury-told-idUSKCN1GO1XZ

Nate Raymond REUTERS
13 Mar 2018

http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-highlight-commitment-antibiotics-and

PRESS RELEASE
08 Mar 2018
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY